Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Using ctDNA test results to guide adjuvant treatment with pembrolizumab can provide benefits in patients with dMMR solid tumors, data suggest.

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

Aethlon Medical announces DSMB completes its scheduled safety review and recommended advancing to the next patient cohort without modification: San Diego Thursday, July 17, 2025, ...

Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival of 54% Strong efficacy signal observed in non-squamous ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...

A phase 2 trial reveals that combining intratumoral BO-112 with pembrolizumab shows potential in treating anti–PD-1-resistant ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with standard concurrent chemoradiotherapy.

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors ...

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced cervical cancer, according to data presented at Society of Gynecologic ...